Amicus Therapeutics to be Acquired by BioMarin for $4.81 Billion in All-Cash Deal

summarizeSummary

Amicus Therapeutics has entered into a definitive agreement to be acquired by BioMarin Pharmaceutical Inc. for $14.50 per share in cash, representing a significant premium to its recent trading prices and above its 52-week high.

check_boxKey Events

• Acquisition Agreement

  Amicus Therapeutics has entered into a definitive Agreement and Plan of Merger to be acquired by BioMarin Pharmaceutical Inc. for $14.50 per share in cash.

• Significant Premium

  The $14.50 per share offer represents a 33% premium over Amicus's closing price of $10.89 on December 18, 2025, and is above the company's 52-week high of $14.38.

• Board Recommendation

  Amicus's Board of Directors unanimously determined the merger is advisable and fair, recommending shareholders vote 'FOR' the Merger Proposal.

• Financing Secured

  BioMarin has secured a $3.65 billion senior secured bridge loan, and the consummation of the merger is not conditioned on BioMarin's ability to obtain financing.

auto_awesomeAnalysis

The acquisition of Amicus Therapeutics by BioMarin Pharmaceutical Inc. for approximately $4.81 billion in cash is a transformative event for Amicus shareholders, offering immediate liquidity and a substantial premium. The $14.50 per share offer represents a 33% premium over the last closing price of $10.89 on December 18, 2025, and is notably above the company's 52-week high of $14.38, indicating a strong valuation for shareholders. The unanimous recommendation by Amicus's Board of Directors, supported by fairness opinions from two financial advisors, underscores the attractiveness of the deal. BioMarin has secured financing, reducing execution risk. The transaction will result in Amicus becoming a wholly-owned subsidiary of BioMarin, delisting its common stock, and ending its public reporting obligations.